Muscarinic agonists and antagonists in the treatment of Alzheimer's disease

被引:67
作者
Greenlee, W [1 ]
Clader, J [1 ]
Asberom, T [1 ]
McCombie, S [1 ]
Ford, J [1 ]
Guzik, H [1 ]
Kozlowski, J [1 ]
Li, S [1 ]
Liu, C [1 ]
Lowe, D [1 ]
Vice, S [1 ]
Zhao, H [1 ]
Zhou, G [1 ]
Billard, W [1 ]
Binch, H [1 ]
Crosby, R [1 ]
Duffy, R [1 ]
Lachowicz, J [1 ]
Coffin, V [1 ]
Watkins, R [1 ]
Ruperto, V [1 ]
Strader, C [1 ]
Taylor, L [1 ]
Cox, K [1 ]
机构
[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA
来源
FARMACO | 2001年 / 56卷 / 04期
关键词
Alzheimer's disease; muscarinic; cholinergic; M-2; receptors;
D O I
10.1016/S0014-827X(01)01102-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairment and personality changes. The development of drugs for the treatment of the cognitive deficits of AD has focused on agents which counteract loss in cholinergic activity. Although symptoms of AD have been successfully treated with acetylcholinesterase inhibitors (tacrine, donepqzil, rivastigmine, galanthamine), limited success has been achieved with direct M-1 agonists, probably due to their lack of selectivity versus other muscarinic receptor subtypes. Muscarinic M-2 antagonists have been reported to increase synaptic levels of acetylcholine after oral administration to rats (e.g. BIBN-99, SCH-57790), but their selectivity versus other muscarinic receptor subtypes is modest. Exploration of a series of piperidinylpiperidines has yielded the potent and selective M-2 antagonist SCH-217443. This antagonist has excellent bioavailability in rats and dogs and shows activity in a rat model of cognition. (C) 2001 Elsevier Science S.A. All rights reserved.
引用
收藏
页码:247 / 250
页数:4
相关论文
共 12 条
[1]  
BOYLE CD, 2001, IN PRESS BIOORG MED
[2]  
Clader J W, 1999, Curr Opin Drug Discov Devel, V2, P311
[3]  
CLADER JW, UNPUB
[4]  
Doods Henri N., 1995, Drugs of the Future, V20, P157
[5]   Muscarinic receptor agonists in Alzheimer's disease - More than just symptomatic treatment? [J].
Fisher, A .
CNS DRUGS, 1999, 12 (03) :197-214
[6]   Cholinergic foundations of Alzheimer's disease therapy [J].
Giacobini, E .
JOURNAL OF PHYSIOLOGY-PARIS, 1998, 92 (3-4) :283-287
[7]  
KOZLOWSKI JA, 2001, IN PRESS BIOORG MED
[8]   SCH 57790:: A novel M2 receptor selective antagonist [J].
Lachowicz, JE ;
Lowe, D ;
Duffy, RA ;
Ruperto, V ;
Taylor, LA ;
Guzik, H ;
Brown, J ;
Berger, JG ;
Tice, M ;
McQuade, R ;
Kozlowski, J ;
Clader, J ;
Strader, CD ;
Murgolo, N .
LIFE SCIENCES, 1999, 64 (6-7) :535-539
[9]   Drug therapy - Treatment of Alzheimer's disease [J].
Mayeux, R ;
Sano, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (22) :1670-1679
[10]   Cholinergic improvement of a naturally-occurring memory deficit in the young rat [J].
Smith, RD ;
Kistler, MK ;
CohenWilliams, M ;
Coffin, VL .
BRAIN RESEARCH, 1996, 707 (01) :13-21